Diabetes and pancreatic cancer

Molecular Carcinogenesis

Volumn 51, Issue 1, 2012, Pages 64-74

  Li, Donghui ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Diabetes; Epidemiology; Pancreatic cancer

Indexed keywords

METFORMIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; DISEASE ASSOCIATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADIPOKINES; DIABETES MELLITUS, TYPE 2; EARLY DETECTION OF CANCER; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; METFORMIN; PANCREATIC NEOPLASMS; PANCREATITIS; RISK FACTORS;

EID: 83455196951     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20771     Document Type: Article

References (159)

1. Noy A, Bilezikian JP. Clinical review 63: Diabetes and pancreatic cancer: Clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab 1994; 79: 1223-1231.
2. Gullo L, Pezzilli R. Diabetes and pancreatic cancer. Pancreas 2004; 28, 451; author reply 451-2.
3. Fisher WE. Diabetes: Risk factor for the development of pancreatic cancer or manifestation of the disease? World J Surg 2001; 25: 503-508.
4. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993; 159: 101-107.
5. Wakasugi H, Funakoshi A, Iguchi H. Clinical observations of pancreatic diabetes caused by pancreatic carcinoma, and survival period. Int J Clin Oncol 2001; 6: 50-54.
6. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134: 981-987.
7. Ekoe JM, Ghadirian P, Simard A, Baillargeon J, Perret C. Diabetes mellitus and pancreatic cancer: A case-control study in greater Montreal, Quebec, Canada. Rev Epidemiol Sante Publique 1992; 40: 447-453.
8. Wynder EL, Mabuchi K, Maruchi N, Fortner JG. A case control study of cancer of the pancreas. Cancer 1973; 31: 641-648.
9. Lin RS, Kessler II. A multifactorial model for pancreatic cancer in man. Epidemiologic evidence. JAMA 1981; 245: 147-152.
10. Gold EB, Gordis L, Diener MD, et al. Diet and other risk factors for cancer of the pancreas. Cancer 1985; 55: 460-467.
11. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: A multisite case-control study. J Chronic Dis 1985; 38: 435-441.
12. Norell S, Ahlbom A, Erwald R, et al. Diabetes, gall stone disease, and pancreatic cancer. Br J Cancer 1986; 54: 377-378.
13. Cuzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int J Cancer 1989; 43: 415-421.
14. Farrow DC, Davis S. Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer 1990; 45: 816-820.
15. Jain M, Howe GR, St Louis P, Miller AB. Coffee and alcohol as determinants of risk of pancreas cancer: A case-control study from Toronto. Int J Cancer 1991; 47: 384-389.
16. Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Karakatsani A, Trichopoulos D. Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control 1993; 4: 375-382.
17. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994; 70: 950-953.
18. Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994; 331: 81-84.
19. Bueno de Mesquita HB, Maisonneuve P, Moerman CJ, Walker AM. Aspects of medical history and exocrine carcinoma of the pancreas: A population-based case-control study in The Netherlands. Int J Cancer 1992; 52: 17-23.
20. Lee CT, Chang FY, Lee SD. Risk factors for pancreatic cancer in orientals. J Gastroenterol Hepatol 1996; 11: 491-495.
21. Frye JN, Inder WJ, Dobbs BR, Frizelle FA. Pancreatic cancer and diabetes: Is there a relationship? A case-controlled study. Aust N Z J Surg 2000; 70: 722-724.
22. Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev 2006; 15: 1458-1463.
23. Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: Case-control study. Am J Gastroenterol 2007; 102: 2696-2707.
24. MacMahon B, Yen S, Trichopoulos D, Warren K, Nardi G. Coffee and cancer of the pancreas. N Engl J Med 1981; 304: 630-633.
25. Bonelli L, Aste H, Bovo P, et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: A case-control study in northern Italy. Pancreas 2003; 27: 143-149.
26. Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80: 1830-1837.
27. Kessler II. Cancer mortality among diabetics. J Natl Cancer Inst 1970; 44: 673-686.
28. Ragozzino M, Melton LJ III, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982; 35: 13-19.
29. Whittemore AS, Paffenbarger RS, Jr., Anderson K, Halpern J. Early precursors of pancreatic cancer in college men. J Chronic Dis 1983; 36: 251-256.
30. Mills PK, Beeson WL, Abbey DE, Fraser GE, Phillips RL. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer 1988; 61: 2578-2585.
31. Hiatt RA, Klatsky AL, Armstrong MA. Pancreatic cancer, blood glucose and beverage consumption. Int J Cancer 1988; 41: 794-797.
32. Balkau B, Barrett-Connor E, Eschwege E, Richard JL, Claude JR, Ducimetiere P. Diabetes and pancreatic carcinoma. Diabete Metab 1993; 19: 458-462.
33. Shibata A, Mack TM, Paganini-Hill A, Ross RK, Henderson BE. A prospective study of pancreatic cancer in the elderly. Int J Cancer 1994; 58: 46-49.
34. Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991; 2: 307-314.
35. Friedman GD, van den Eeden SK. Risk factors for pancreatic cancer: An exploratory study. Int J Epidemiol 1993; 22: 30-37.
36. Chow WH, Gridley G, Nyren O, et al. Risk of pancreatic cancer following diabetes mellitus: A nationwide cohort study in Sweden. J Natl Cancer Inst 1995; 87: 930-931.
37. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-1365.
38. Lund Nilsen TI, Johnsen R, Vatten LJ. Socio-economic and lifestyle factors associated with the risk of prostate cancer. Br J Cancer 2000; 82: 1358-1363.
39. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, Virtamo J, Albanes D. A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). Cancer Causes Control 2002; 13: 417-426.
40. Lin Y, Tamakoshi A, Kawamura T, et al. Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and medical history: Findings from the Japan collaborative cohort study for evaluation of cancer risk. Int J Cancer 2002; 99: 742-746.
41. Inoue M, Tajima K, Takezaki T, et al. Epidemiology of pancreatic cancer in Japan: A nested case-control study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Int J Epidemiol 2003; 32: 257-262.
42. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003; 124: 1292-1299.
43. Batty GD, Shipley MJ, Marmot M, Smith GD. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: Findings from the original Whitehall study. Cancer Causes Control 2004; 15: 873-881.
44. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160-1167.
45. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA 2008; 300: 2754-2764.
46. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273: 1605-1609.
47. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-2083.
48. Li D, Tang H, Hassan M, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: A pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22: 189-197.
49. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005; 294: 2872-2878.
50. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008; 114: 63-70.
51. Smith GD, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 1992; 136: 1110-1114.
52. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000; 283: 2552-2558.
53. Pour PM, Kazakoff K. Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model. Am J Pathol 1996; 149: 1017-1025.
54. Pour PM, Donnelly K, Stepan K. Modification of pancreatic carcinogenesis in the hamster model. 3. Inhibitory effect of alloxan. Am J Pathol 1983; 110: 310-314.
55. Pour PM, Patil K. Modification of pancreatic carcinogenesis in the hamster model. X. Effect of streptozotocin. J Natl Cancer Inst 1983; 71: 1059-1065.
56. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin [see comment]. Gastroenterology 2001; 120: 1263-1270.
57. Ding XZ, Fehsenfeld DM, Murphy LO, Permert J, Adrian TE. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 2000; 21: 310-320.
58. Ooi GT, Tseng LY, Tran MQ, Rechler MM. Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol 1992; 6: 2219-2228.
59. Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PD. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem 1991; 266: 18868-18876.
60. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles. Cancer Res 1995; 55: 2007-2011.
61. Ohmura E, Okada M, Onoda N, et al. Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res 1990; 50: 103-107.
62. Stoeltzing O, Liu W, Reinmuth N, et al. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 2003; 163: 1001-1011.
63. Zeng H, Datta K, Neid M, et al. Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 2003; 302: 46-55.
64. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
65. Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol Biomarkers Prev 2004; 13: 438-444.
66. Wolpin BM, Michaud DS, Giovannucci EL, et al. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer 2007; 97: 98-104.
67. Wolpin BM, Michaud DS, Giovannucci EL, et al. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res 2007; 67: 7923-7928.
68. Suzuki H, Li Y, Dong X, Hassan MM, Abbruzzese JL, Li D. Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 3467-3473.
69. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7, 12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 1972; 32: 226-232.
70. Hine RJ, Srivastava S, Milner JA, Ross SA. Nutritional links to plausible mechanisms underlying pancreatic cancer: A conference report. Pancreas 2003; 27: 356-366.
71. Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Glycemic index, glycemic load, and risk of digestive tract neoplasms: A systematic review and meta-analysis. Am J Clin Nutr 2009; 89: 568-576.
72. Ogihara T, Asano T, Katagiri H, et al. Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase. Diabetologia 2004; 47: 794-805.
73. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
74. Gopaul NK, Manraj MD, Hebe A, et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001; 44: 706-712.
75. Manning PJ, Sutherland WH, Walker RJ, et al. Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diabetes Care 2004; 27: 2166-2171.
76. Midaoui AE, Elimadi A, Wu L, Haddad PS, de Champlain J. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens 2003; 16: 173-179.
77. Blendea MC, Jacobs D, Stump CS, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 2005; 288: E353-E359.
78. Busserolles J, Rock E, Gueux E, Mazur A, Grolier P, Rayssiguier Y. Short-term consumption of a high-sucrose diet has a pro-oxidant effect in rats. Br J Nutr 2002; 87: 337-342.
79. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
80. Tirosh A, Potashnik R, Bashan N, Rudich A. Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem 1999; 274: 10595-10602.
81. Greer JB, Whitcomb DC, Greer JB, Whitcomb DC. Inflammation and pancreatic cancer: An evidence-based review. Curr Opin Pharmacol 2009; 9: 411-418.
82. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-2180.
83. Gallagher EJ, LeRoith D, Gallagher EJ, LeRoith D. Insulin, insulin resistance, obesity, and cancer. Curr Diabetes Rep 2010; 10: 93-100.
84. Aljada A, Ghanim H, Mohanty P, Syed T, Bandyopadhyay A, Dandona P. Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am J Clin Nutr 2004; 80: 51-57.
85. Dhindsa S, Tripathy D, Mohanty P, et al. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells. Metabolism 2004; 53: 330-334.
86. Mohanty P, Ghanim H, Hamouda W, Aljada A, Garg R, Dandona P. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr 2002; 75: 767-772.
87. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009; 18: 2569-2578.
88. Lago R, Gómez R, Lago F, et al. Leptin beyond body weight regulation-Current concepts concerning its role in immune function and inflammation. Cell Immunol 2008; 252: 139-145.
89. Smith TJ, Smith TJ. Insulin-like growth factor-I regulation of immune function: A potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010; 62: 199-236.
90. Wohlfert EA, Nichols FC, Nevius E, Clark RB. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: Enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol 2007; 178: 4129-4135.
91. Duffy DL. Genetic determinants of diabetes are similarly associated with other immune-mediated diseases. Curr Opin Allergy Clin Immunol 2007; 7: 468-474.
92. Petersen GM, Amundadottir L, Fuchs CS, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010; 42: 224-228.
93. Annicotte JS, Fayard E, Swift GH, et al. Pancreatic-duodenal homeobox 1 regulates expression of liver receptor homolog 1 during pancreas development. Mol Cell Biol 2003; 23: 6713-6724.
94. Brissova M, Shiota M, Nicholson WE, et al. Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem 2002; 277: 11225-11232.
95. Glucksmann MA, Lehto M, Tayber O, et al. et al. Novel mutations and a mutational hotspot in the MODY3 gene. Diabetes 1997; 46: 1081-1086.
96. Shih DQ, Heimesaat M, Kuwajima S, Stein R, Wright CV, Stoffel M. Profound defects in pancreatic beta-cell function in mice with combined heterozygous mutations in Pdx-1, Hnf-1alpha, and Hnf-3beta. Proc Natl Acad Sci USA 2002; 99: 3818-3823.
97. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin [see comment]. Diabetes Care 2006; 29: 254-258.
98. Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: A case-control study. Acta Diabetol 2009; 46: 279-284.
99. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM. New users of metformin are at low risk of incident cancer. Diabetes Care 2009; 32: 1620-1625.
100. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
101. Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33: 322-326.
102. Decensi A, Puntoni M, Goodwin P, et al. Cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 3: 1451-1461.
103. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482-488.
104. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8: 909-915.
105. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009; 69: 6539-6545.
106. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010; 49: 662-671.
107. Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40: 685-693.
108. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res 2010; 3: 1066-1076.
109. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res 2010; 3: 1077-1083.
110. Pollak M. Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila, PA) 2010; 3: 1060-1065.
111. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ann Intern Med 2002; 137: 25-33.
112. Hundal RS, Inzucchi SE. Metformin: New understandings, new uses. Drugs 2003; 63: 1879-1894.
113. Ersoy C, Kiyici S, Budak F, et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract 2008; 81: 56-60.
114. De Jager J, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: A randomized, placebo-controlled trial. J Intern Med 2005; 257: 100-109.
115. Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006; 26: 611-617.
116. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-1350.
117. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453.
118. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-226.
119. Williams T, Brenman JE. LKB1 and AMPK in cell polarity and division. Trends Cell Biol 2008; 18: 193-198.
120. Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9: 218-224.
121. Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009; 460: 103-107.
122. Prlic M, Bevan MJ. Immunology: A metabolic switch to memory. Nature 2009; 460: 41-42.
123. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
124. Gerstein HC. Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA 2010; 303: 446-447.
125. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699-1708.
126. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: A consensus report. CA Cancer J Clin 2010; 60: 207-221.
127. Ahren B, Andren-Sandberg A. Glucose tolerance and insulin secretion in experimental pancreatic cancer in the Syrian hamster. Res Exp Med (Berl) 1993; 193: 21-26.
128. Cersosimo E, Pisters PW, Pesola G, McDermott K, Bajorunas D, Brennan MF. Insulin secretion and action in patients with pancreatic cancer. Cancer 1991; 67: 486-493.
129. Fogar P, Basso D, Panozzo MP, et al. C-peptide pattern in patients with pancreatic cancer. Anticancer Res 1993; 13: 2577-2580.
130. Murphy R, Smith FH. Abnormal carbohydrate metabolism in pancreatic carcinoma. Med Clin North Am 1963; 47: 397-405.
131. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80: 1047-1050.
132. Basso D, Brigato L, Veronesi A, Panozzo MP, Amadori A, Plebani M. The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res 1995; 15: 2585-2588.
133. Basso D, Valerio A, Brigato L, et al. An unidentified pancreatic cancer cell product alters some intracellular pathways of glucose metabolism in isolated rat hepatocytes. Pancreas 1997; 15: 132-138.
134. Basso D, Valerio A, Seraglia R, et al. Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas 2002; 24: 8-14.
135. Basso D, Greco E, Fogar P, et al. Pancreatic cancer-derived S-100A8 N-terminal peptide: A diabetes cause? Clin Chim Acta 2006; 372: 120-128.
136. Wang F, Adrian TE, Westermark G, Gasslander T, Permert J. Dissociated insulin and islet amyloid polypeptide secretion from isolated rat pancreatic islets cocultured with human pancreatic adenocarcinoma cells. Pancreas 1999; 18: 403-409.
137. Permert J, Larsson J, Westermark GT, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994; 330: 313-318.
138. Brand RE, Ding XZ, Young CM, et al. The specificity of amylin for the diagnosis of pancreatic adenocarcinoma. Int J Gastrointest Cancer 2002; 31: 123-128.
139. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 2001; 121: 640-645.
140. Saruc M, Iki K, Pour PM, Saruc M, Iki K, Pour PM. Morphometric studies in human pancreatic cancer argues against the etiological role of type 2 diabetes in pancreatic cancer. Histol Histopathol 2010; 25: 423-432.
141. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: A population-based study. Gastroenterology 2005; 129: 504-511.
142. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: Prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134: 95-101.
143. Satake K, Takeuchi T, Homma T, Ozaki H. CA 19-9 as a screening and diagnostic tool in symptomatic patients: The Japanese experience. Pancreas 1994; 9: 703-706.
144. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19: 182-186.
145. Huang H, Dong X, Kang MX, et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol 2010; 105: 1661-1669.
146. Stein KB, Snyder CF, Barone BB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: A systematic review and meta-analysis. Dig Dis Sci 2010; 55: 1839-1851.
147. Wu CH, Wu TY, Li CC, et al. Impact of diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma: A retrospective cohort study. Ann Surg Oncol 2010; 17: 2175-2183.
148. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003; 21: 433-440.
149. Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004; 100: 1179-1185.
150. Wolf I, Sadetzki S, Gluck I, et al. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer 2006; 42: 1077-1082.
151. Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005; 2: 48-53.
152. Ganti AK, Potti A, Koch M, et al. Predictive value of clinical features at initial presentation in pancreatic adenocarcinoma: A series of 308 cases. Med Oncol 2002; 19: 233-237.
153. Kim TD, Oh HJ, Kim KH, et al. Clinical characteristics of pancreatic cancer according to the presence of diabetes mellitus. Korean J Gastroenterol 2004; 43: 35-40.
154. Pedrazzoli S, Sperti C, Pasquali C. Prediction of resectability and of surgical risk in pancreatic carcinoma; conditioning factors of survival after resective intervention. Chir Ital 1994; 46: 30-38.
155. Andren-Sandberg A, Ihse I. Factors influencing survival after total pancreatectomy in patients with pancreatic cancer. Ann Surg 1983; 198: 605-610.
156. Kang SP, Saif MW, Kang SP, Saif MW. Clinical outcome of pancreatic cancer patients with diabetes mellitus: Is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP 2010; 11: 334-335.
157. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009; 301: 2553-2562.
158. McWilliams RR, Matsumoto ME, Burch PA, et al. Obesity adversely affects survival in pancreatic cancer patients. Cancer 2010; 116: 5054-5062.
159. Li D, Abbruzzese JL. New strategies in pancreatic cancer: Emerging epidemiologic and therapeutic concepts. Clin Cancer Res 2010; 16: 4313-4318.